Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders
Yurui Ma, Evon Poon, Chenchen Jin, Barbara Martins Da Costa, Yuewei Xu, Sadiya Quazi, Nikolaos Zourdoumis, Chiharu Wickremesinghe, Louis Chesler, Hector C. Keun, Anke M. Nijhuis
This paper combines RBM39 degradation and SRPK1 inhibition to disrupt RNA splicing in neuroblastoma, showing synergistic anti-cancer effects in cell lines and a mouse model.
Cell Reports · Jan 1, 2026Peer-reviewedCancer Biology